(Q38118157)

29 August 2017

Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system (English)

1 reference

29 August 2017

B Solun

1

1 reference

29 August 2017

D Marcoviciu

series ordinal

2

1 reference

29 August 2017

D Dicker

series ordinal

3

1 reference

29 August 2017

1 August 2013

1 reference

Current cardiology reports

29 August 2017

1 reference

29 August 2017

15

1 reference

29 August 2017

8

1 reference

29 August 2017

382

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-013-0382-2

29 August 2017

0 references

cites work

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Cardiovascular effects of the DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

On some aspects of Adsorption Phenomena, with especial reference to the Action of Electrolytes and to the Ash-Constituents of Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Stimulation of incretin secretion by dietary lipid: is it dose dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Abnormalities in insulin secretion in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Pancreatic alpha-cell dysfunction in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Skeletal muscle insulin resistance is the primary defect in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Adenovirus-mediated stromal cell-derived factor-1 alpha gene transfer improves cardiac structure and function after experimental myocardial infarction through angiogenic and antifibrotic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0382-2

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

12 December 2020

[Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas]

1 reference

12 December 2020

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

12 December 2020

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

12 December 2020

The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart

1 reference

12 December 2020

1 reference

12 December 2020

Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice

1 reference

12 December 2020

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes

1 reference

12 December 2020

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

12 December 2020

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

1 reference

12 December 2020

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

12 December 2020

10.1007/S11886-013-0382-2

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference